Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma
Min Li,1 Weiyue Zhang,2 Birong Wang,3 Yang Gao,1 Zifang Song,1 Qi Chang Zheng1 1Department of Hepatobiliary Surgery, Union Hospital, 2The First Clinic Institute, Tongji Medical College, Huazhong University of Science and Technology, 3Department of Breast and Thyroid Surgery, Puai Hospital, Wuhan, T...
Guardado en:
Autores principales: | Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/83cdef968cbc411081c9586f923e4b98 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Overexpression of PIK3R1 promotes hepatocellular carcinoma progression
por: Ai,Xuejun, et al.
Publicado: (2018) -
A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma
por: Farinha D, et al.
Publicado: (2021) -
Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
por: L. V. Bolotina
Publicado: (2020) -
Identification of Novel Ligands for Targeted Antifibrotic Therapy of Chronic Pancreatitis
por: Hung J, et al.
Publicado: (2021) -
Dual-Effect of Magnetic Resonance Imaging Reporter Gene in Diagnosis and Treatment of Hepatocellular Carcinoma
por: Zhou J, et al.
Publicado: (2020)